Urinary tract infections (UTIs) are often recurrent. The organism does not always establish an effective line of defense that protects from reinfection. The key lies in two reservoirs of bacteria and how tissue-resident memory T cells (TRMs) trigger the immune response. A recent paper from the Pasteur Institute in France describes how these cells mediate immunity to defeat reinfection.
Shanghai Euregen Biopharma Co. Ltd. has divulged menin (MEN1)/MLL interaction inhibitors reported to be useful for the treatment of cancer, autoimmune disease, diabetes and nonalcoholic fatty liver disease).
Ubix Therapeutics Inc. has identified proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to a Bruton tyrosine kinase (BTK) targeting moiety via linker acting as BTK degradation inducers reported to be useful for the treatment of cancer and autoimmune disease.
Celros Biotech Co. Ltd. has synthesized cytochrome b-245 heavy chain (CYBB; NOX2) and NADPH oxidase 4 (NOX4) inhibitors reported to be useful for the treatment of atherosclerosis, Alzheimer’s disease, cirrhosis, diabetes, cancer, glomerulonephritis, psoriasis and rheumatoid arthritis, among others.
Sanford-Burnham Medical Research Institute has disclosed baculoviral IAP repeat-containing protein 7 (BIRC7; ML-IAP) inhibitors reported to be useful for the treatment of cancer.
Vascular smooth muscle cell (VSMC) activation plays a crucial role in the development of several vascular diseases, including intimal hyperplasia indicative of restenosis. Fragile X-related protein 1 (FXR1) is a muscle-enhanced RNA binding protein that has been proposed to regulate inflammation negatively and is overexpressed in injured arteries. However, the role of FXR1 in vascular disease remains unclear.
RSS
